secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001437749-22-019616
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLife Q2 rev $40.5M (+30% YoY); net loss $72.6M on $69.9M impairment; guides FY22 rev $160-166M
--------------------------------------------------------------------------------

- Q2 2022 revenue $40.5M, up 30% YoY; organic growth 44%; biopreservation media revenue up 46%.
- GAAP net loss $72.6M ($1.71 loss per share) vs net income $7.9M ($0.19 EPS) in Q2 2021; includes $69.9M non-cash impairment charge.
- Adjusted EBITDA positive $1.5M in Q2 2022 vs $3.7M in Q2 2021; adjusted gross margin 36% vs 43% prior year.
- Full-year 2022 revenue guidance updated to $160M-$166M (34-39% growth) with positive adjusted EBITDA expected.
- Cash and marketable securities $46.6M as of June 30, 2022; down $12.9M from March 31 due to working capital and capex.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000143774922019616/0001437749-22-019616-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000143774922019616/bioli20220809_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-019616

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer